- Previous Close
6.01 - Open
5.76 - Bid 4.77 x 100
- Ask 6.59 x 100
- Day's Range
5.56 - 5.76 - 52 Week Range
4.31 - 10.74 - Volume
2,932 - Avg. Volume
9,240 - Market Cap (intraday)
8.375M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.81 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
www.precipiodx.com51
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PRPO
View MorePerformance Overview: PRPO
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRPO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRPO
View MoreValuation Measures
Market Cap
9.29M
Enterprise Value
9.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.52
Price/Book (mrq)
0.78
Enterprise Value/Revenue
0.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.23%
Return on Assets (ttm)
-16.44%
Return on Equity (ttm)
-24.05%
Revenue (ttm)
17.41M
Net Income Avi to Common (ttm)
-3M
Diluted EPS (ttm)
-1.81
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05M
Total Debt/Equity (mrq)
10.72%
Levered Free Cash Flow (ttm)
-252.62k